Virax Biolabs Group First Half 2025 Earnings: US$0.89 loss per share (vs US$1.64 loss in 1H 2024)

Virax Biolabs Group (NASDAQ:VRAX) First Half 2025 Results

Key Financial Results

• Net loss: US$2.76m (loss narrowed by 5.3% from 1H 2024).
• US$0.89 loss per share (improved from US$1.64 loss in 1H 2024).

All figures shown in the chart above are for the trailing 12 month (TTM) period

Virax Biolabs Group shares are up 5.2% from a week ago.

Risk Analysis

We don't want to rain on the parade too much, but we did also find 5 warning signs for Virax Biolabs Group that you need to be mindful of.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.